Search Product Liability Law & Strategy

We found 2,777 results for "Product Liability Law & Strategy"...

KEYWORDS

April 29, 2010

Recent rulings of interest to you and your practice.

Practice Tip: Failure-to-Warn Causation and The Learned Intermediary

April 29, 2010

In pharmaceutical and medical device litigation, the failure-to-warn claim continues to be among the most common causes of action. This article examines some of the key factors involved in proving causation in a failure-to-warn case, and discusses recent case law in this area.

Recent Class Certification Decisions Present New Opportunities and Challenges for Defendants

April 29, 2010

From a mass tort product liability defense perspective, the trend away from class certification is welcome news. However, any pronouncement that class actions are dead is premature.

Cybercrime Poses New Risks in Commercial Banking

April 29, 2010

This article discusses the handling of electronic fund transfers under the Uniform Commercial Code, online banking customer authentication methods, and recent litigation between banks and small and medium-sized businesses that were victims of cybertheft.

Avoiding FCPA Liability with a Robust Compliance Program

April 28, 2010

With crystal clarity, the U.S. Government has signaled its intentions regarding enforcement of the Foreign Corrupt Practices Act (FCPA): far greater resources devoted to FCPA investigations, and far harsher penalties for FCPA violations.

In the Spotlight: Landlords and Tenants Mediate Conflicts

April 28, 2010

Whether or not tenants have protective lease provisions, conflicts frequently arise with landlords facing economic stresses, and more often arise with the successor landlord, foreclosure purchaser. These conflicts threaten ' and often result in ' litigation.

Movers & Shakers

March 30, 2010

Who's doing what; who's going where.

Case Notes

March 30, 2010

Analyses of key cases of importance.

'Failure to Warn' Claims Against Generic Manufacturers Not Preempted By Federal Law

March 30, 2010

The U.S. Court of Appeals for the Eighth Circuit recently held that "failure to warn" claims brought against generic manufacturers of Reglan' (a prescription drug used to treat certain gastric disorders) were not preempted by federal law and could, therefore, proceed to discovery.

Practice Tip: FDA Issues Draft Guidance for REMS

March 30, 2010

The first part of this article discussed the background of REMS (Risk Evaluation and Mitigation Strategies) and provided a summary of the Draft Guidance. The conclusion herein explains the second part of the procedure, including proposed modifications and communicating with the FDA.

MOST POPULAR STORIES

Strategy vs. Tactics: Two Sides of a Difficult Coin
With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.
Read More ›
The DOJ's New Parameters for Evaluating Corporate Compliance Programs
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
Read More ›
Use of Deferred Prosecution Agreements In White Collar Investigations
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
Read More ›
The DOJ's Corporate Enforcement Policy: One Year Later
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Read More ›
Artificial Intelligence
Disney-OpenAI’s Sora Deal: What it Signals for Licensing and Responsible AI
The Walt Disney Co.’s newly announced, three-year licensing agreement with OpenAI to bring more than 200 characters from Disney, Marvel, Pixar and Star Wars to Sora marks a pivotal moment at the intersection of intellectual property and generative AI. For rights holders, platforms, and brands, the deal illustrates an emerging blueprint for commercializing iconic IP in AI-native formats while attempting to manage legal, regulatory, and reputational risk.
Read More ›

Site Search

Follow Us

Law.com Subscribers SAVE 30%

Search

MOST POPULAR STORIES